Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation From the Vault, the group discusses NITs and what will change between now and when this conference convenes next year.
Surfing the NASH Tsunami begins its fourth season by covering Day One of the highly anticipated NASH-TAG 2023. In this episode, a group of leading KOLs discuss the first day of presentations, with particular focus on NITs, and a group of patient advocates discuss how new information and successful drug trials are changing demand from physicians, patients and caregivers.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Mazen Noureddin to reflect on opening a new research institute, increasing optimism around drug trials and the use of NITs, work in the novel mitochondrial uncoupling agent HU6, the NAIL-NIT consortium and more.
Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022. In this final conversation, Jörn Schattenberg, Louise Campbell and Roger Green discuss NAIL-NIT retrospective analysis data and the role of consortia in reshaping the focus of NITs.
Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022 featuring the impressions of Jörn Schattenberg, Louise Campbell and Roger Green. This discussion looks at the return to in-person conferences and events, NICE on FibroScan, progress in NITs, potential pathway developments and much more.
In this conversation From Inside the Vault, NAIL-NIT co-leads Stephen Harrison and Mazen Noureddin and retrospective analysis co-leads Naim Alkhouri and Jörn Schattenberg join Louise Campbell and Roger Green to discuss designs and plans for NAIL-NIT retrospective analysis.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this final conversation, the group explores the rest of the Day Two program, focusing on the development of an NIT diagnostic pathway. Finally, each offers their closing remarks on being a part of the 8th Paris NASH Meeting and what the future looks like in this space.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses presentations on adaptive trial strategies, trial recruitment and reducing screen fail rates, and the impact of educating patients on better self-care.
Naim Alkhouri and Mazen Noureddin join the Surfers to discuss the future role of Combination Agents with NASH therapy, stemming from their recently published article, Safety and efficacy of combination therapy with semaglutide,cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The conversation focuses more broadly on the benefits and future of combination therapies for NASH patients.
From February of this year, Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to discuss the formation of the new NAIL-NIT consortium, led by Stephen and Mazen. This conversation focuses on the specific challenges inherent in the NAS scores.
